A Phase 1 interventional study of Sodium Citrate and Treprostinil in Type 1 Diabetes Mellitus, sponsored by Eli Lilly and Company. Completed at 2 sites in Germany. Open to participants aged 18 Years to 69 Years. Per ClinicalTrials.gov, last updated 2023-10-04.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company — 4 open to participants now, 6 under way, 4 of them phase 3. Diabetes Mellitus, Type 1 · Eli Lilly and Company.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, this one is the 41st largest by enrollment of the 72 interventional ones that give a count, is one of 2 that started in 2021, is one of 33 in phase 1, and was the 64th registered.
3,755 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.
Browse Diabetes Mellitus, Type 1 studies →4 of the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company are open now, in 12 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18–70
Eli Lilly and Company · Sites in United States, Australia, Belgium and 17 more countries
Ages 1–35
Eli Lilly and Company · Sites in United States, Australia, Belgium and 16 more countries
Ages 1–35
Eli Lilly and Company · Sites in Germany
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 414 Diabetes Mellitus, Type 1 studies recruiting now, 128 (31%) set no upper age limit and 260 (63%) stop at 75 or younger; 187 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 69 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
75 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 8 · Phase 3 25 · Phase 4 2
First in 2002; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 40 is close to the median of 40 across 2,821 interventional studies indexed under Diabetes Mellitus, Type 1.
Median enrollment 62 across the 72 interventional studies, 28 across the 3 observational. Of the 66 that completed or were terminated, 49 (74%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
4 of the studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06962280Phase 3Eli Lilly and CompanyA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT07803744Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) in Participants With Type 1 Diabetes Mellitus and Overweight or Obesity | 2026-12 |
| NCT06945406Eli Lilly and CompanyA Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes | 2027-03 |
Add all 4 to your calendar (.ics) → With an account.
Among the 75 studies in Diabetes Mellitus, Type 1 by Eli Lilly and Company, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the effect of excipients sodium citrate and treprostinil without insulin on local infusion site pain in participants with type 1 diabetes mellitus (T1DM) on continuous subcutaneous insulin infusion (CSII). The study may last up to 36 days including a screening period and 3 visits.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants had cannulas inserted into each of the designated infusion sites (6 millimeter (mm) for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated subcutaneously (SC) with 15 millimolar (mM) sodium citrate and 1 microgram per milliliter (μg/mL) treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 unit per hour (U/h). The same procedure occurred at subsequent infusion sites with an approximately 30-minute (min) interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride
Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride
Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride
Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 units per U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride
Participants had cannulas inserted into each of the designated infusion sites (6 mm for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen), and the first infusion site was initiated with 15 mM sodium citrate and 1 μg/mL treprostinil in Humalog diluent with 5 mM magnesium chloride (without insulin) solution at a basal infusion rate of 1 U/h. The same procedure occurred at subsequent infusion sites with an approximately 30-minute interval between each initiation. Approximately 3, 6, and 9 hours after the start of the basal infusion, a bolus dose of 15 U was delivered at quick bolus speed (15 U/min) to each infusion site according to the treatment sequence with an approximately 30-minute interval between infusion sites.
Drug: Sodium Citrate · Drug: Treprostinil · Drug: Humalog diluent · Drug: Magnesium Chloride
Administered SC infusion.
Administered SC infusion.
Administered SC infusion.
Administered SC infusion.
Visual Analog Scale (VAS) Pain Score in the Abdominal, Arm, Thigh, and Buttock Areas
The Infusion site pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).
Time frame: Day 1: 1 min post bolus.
Participants were randomly assigned to 1 of 5 infusion site sequence below and received the study treatment in each period. Cannulas were inserted into each of the designated infusion sites (6 millimeter (mm) for all the sites. Additionally for the abdominal area only, a 9 mm cannula was also inserted into the opposite side of the lower abdomen).
| Milestone | Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh | Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock | Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region | Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm | Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 |
| Received at least one infusion | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh | Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock | Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region | Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm | Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 |
| Received at least one infusion | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh | Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock | Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region | Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm | Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 |
| Received at least one infusion | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh | Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock | Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region | Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm | Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 |
| Received at least one infusion | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
| Milestone | Sequence 1:Arm Region,Abdomen 6mm,Buttock,Abdomen 9mm,Thigh | Sequence 2:Abdomen 6mm,Abdomen 9mm,Arm Region,Thigh,Buttock | Sequence 3:Abdomen 9mm,Thigh,Abdomen 6mm,Buttock,Arm Region | Sequence 4:Thigh,Buttock,Abdomen 9mm,Arm Region,Abdomen 6mm | Sequence 5:Buttock,Arm Region,Thigh,Abdomen 6mm,Abdomen 9mm |
|---|---|---|---|---|---|
| Started | 8 | 8 | 8 | 8 | 8 |
| Received at least one infusion | 8 | 8 | 8 | 8 | 8 |
| Completed | 8 | 8 | 8 | 8 | 8 |
| Not completed | 0 | 0 | 0 | 0 | 0 |
The Infusion site pain VAS score is a participant administered single item scale designed to measure pain using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's pain is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no pain) to 100 mm (worst imaginable pain).
| millimeter | Treatment Given to Arm Region | Treatment Given to Thigh | Treatment Given to Abdomen (6 mm) | Treatment Given to Abdomen (9 mm) | Treatment Given to Buttock |
|---|---|---|---|---|---|
| 1 min post bolus (Bolus time: 3 hours) | 3.4 ± 182 | 2.0 ± 119 | 1.8 ± 112 | 1.9 ± 119 | 2.4 ± 167 |
| 1 min post bolus (Bolus time: 6 hours) | 3.7 ± 164 | 2.6 ± 137 | 2.3 ± 151 | 2.0 ± 113 | 3.3 ± 161 |
| 1 min post bolus (Bolus time: 9 hours) | 4.8 ± 211 | 3.4 ± 155 | 2.5 ± 141 | 2.4 ± 141 | 3.8 ± 196 |
Collected over Up to 9 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment Given to Arm Region | 0/40 (0%) | 0/40 (0%) | 5/40 (12.5%) |
| Treatment Given to Thigh | 0/40 (0%) | 0/40 (0%) | 9/40 (22.5%) |
| Treatment Given to Abdomen (6 mm) | 0/40 (0%) | 0/40 (0%) | 4/40 (10%) |
| Treatment Given to Abdomen (9 mm) | 0/40 (0%) | 0/40 (0%) | 4/40 (10%) |
| Treatment Given to Buttock | 0/40 (0%) | 0/40 (0%) | 3/40 (7.5%) |
| Event | Treatment Given to Arm Region | Treatment Given to Thigh | Treatment Given to Abdomen (6 mm) | Treatment Given to Abdomen (9 mm) | Treatment Given to Buttock |
|---|---|---|---|---|---|
| Infusion site reactionGeneral disorders | 5/40 | 9/40 | 4/40 | 4/40 | 3/40 |
All participants who received at least one Infusion.
| Age, Continuous(years) | Overall |
|---|---|
| Mean | 40.5 ± 12.0 |
| Sex: Female, Male(Participants) | Overall |
|---|---|
| Female | 10 |
| Male | 30 |
| Race (NIH/OMB)(Participants) | Overall |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 40 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Overall |
|---|---|
| Germany | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2021 to primary completion in Dec 2021, 1 month.
Results were first posted in Oct 2023, 1 year 9 months after primary completion.
Of 97 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 13. This study's 1 month is below that.
Counting every sponsor, half of 152 studies reached it within 12 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sodium Citrate · Treprostinil · Magnesium Chloride